ADVANCED VISION, SAFE TREATMENT IN “RESPIRATORY AND BIOTECHNOLOGY”
ARVEN Pharmaceuticals, which started its activities at the end of 2013, planned to operate primarily in the fields of respiratory diseases and disease treatment that require biotechnology products in the near future. It has shaped its works with the principle of “Advanced vision, safe treatment in Respiratory and Biotechnology “.
ARVEN Pharmaceuticals, together with Sanovel Pharmaceuticals, has taken its place within the Toksöz Group while aiming at becoming one of the most important institutions of the Turkish Pharmaceutical Industry with its strong and high production capacity in compliance with international standards in terms of its scientific and technological infrastructure as well as human resources.
ARVEN Pharmaceuticals plans to add new products to its existing product portfolio in “Respiratory and Biotechnology” in a short time. With this aim, the company employs approximately 200 people with its production facility established in an area of 30.000 m2 in Kırklareli which started its operations in 2017 and R&D facilities established in Selimpaşa.